Medtronic To Pay $55M In HeartWare Investor Suit
Executive Summary
Device-giant Medtronic has agreed to pay $54.5m to settle a class-action suit filed by investors in HeartWare, which Medtronic bought in 2016. The plaintiffs say HeartWare misled investors about the safety of a miniaturized heart pump under development.
You may also be interested in...
Medtronic Ups Its Heart-Failure Competitive Strength With HeartWare Buy
The deal gives Medtronic its first ventricular-assist devices and gives struggling HeartWare a needed boost.
HeartWare Updates Status Of Battles On Several Fronts
HeartWare is counting on its established HVAD technology to carry it through a difficult period as it struggles to relaunch the clinical trial of the MVAD miniaturized ventricular assist device.
Contingency Planning: Guidance Doc Details Handling Clinical Trials During Emergencies
The agency urges sponsors to keep patient safety “first and foremost” in determining how to continue a clinical trial during a natural disaster, public health emergency, or other crisis.